Monday, April 28, 2014
Private biotechs have raised
$3.1 billion since the start of the year, double the $1.5 billion raised in the
same period last year. At least one investor contacted by BioCentury expects
the pace to continue in part because LPs are redeploying returns from prior
healthcare investments to new biotech funds.
That would mark a dramatic
change from two or three years ago, when biotech VCs were struggling to lure